Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cullinan Therapeutics

7.76
+0.01000.13%
Post-market: 7.760.00000.00%16:34 EDT
Volume:1.44M
Turnover:11.22M
Market Cap:457.95M
PE:-2.51
High:7.98
Open:7.75
Low:7.63
Close:7.75
Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sight Sciences (SGHT) and Cullinan Management (CGEM)

TIPRANKS
·
17 Jun

Cullinan Management Holds Annual Stockholders Meeting

TIPRANKS
·
13 Jun

Cullinan Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
13 Jun

Cullinan Oncology Price Target Announced at $22.00/Share by Stifel

Dow Jones
·
11 Jun

Cullinan Therapeutics Inc : Stifel Resumes Coverage With Buy Rating; Price Target $22

THOMSON REUTERS
·
11 Jun

Cullinan Therapeutics resumed with a Buy at Stifel

TIPRANKS
·
11 Jun

Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), aTyr Pharma (ATYR) and Pharvaris (PHVS)

TIPRANKS
·
09 Jun

Cullinan Management’s Strategic Expansion and Promising Velinotamig Results Justify Buy Rating

TIPRANKS
·
06 Jun

Cullinan Management (CGEM) Receives a Buy from Wedbush

TIPRANKS
·
05 Jun

Cullinan Management: Strategic Licensing and Financial Stability Drive Buy Rating

TIPRANKS
·
05 Jun

BRIEF-Cullinan Therapeutics Licenses Rights to Velinotamig

Reuters
·
05 Jun

Cullinan Therapeutics Inc. Enters Exclusive Licensing Agreement with Genrix Bio for Velinotamig Development in Autoimmune Diseases

Reuters
·
05 Jun

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage Bcma-Directed Bispecific T Cell Engager, From Genrix Bio for Development in Autoimmune Diseases

THOMSON REUTERS
·
05 Jun

Cullinan Therapeutics Inc - to Pay $20 Mln Upfront License Fee to Genrix Bio

THOMSON REUTERS
·
05 Jun

Cullinan Therapeutics Inc - Expects Cash Resources to Last Into 2028

THOMSON REUTERS
·
05 Jun

Cullinan Therapeutics : Genrix to Receive up to an Additional $400M in Sales-Based Milestones

THOMSON REUTERS
·
05 Jun

Cullinan Therapeutics Unveils Corporate Presentation Highlighting Strategic Advancements in Autoimmune and Oncology Programs

Reuters
·
03 Jun

Cullinan Therapeutics Inc. Presents Zipalertinib Update and Strategic Directions at ASCO 2025

Reuters
·
03 Jun

Promising Potential of Zipalertinib Drives Buy Rating for Cullinan Management

TIPRANKS
·
02 Jun

BRIEF-Cullinan Therapeutics Inc - Taiho Oncology And Cullinan Therapeutics Publish Positive Rezilient1 Trial Results

Reuters
·
01 Jun